Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety

Drug Delivery

Volumn 22, Issue 1, 2015, Pages 21-36

  El Ridy, Mohammed Shafik ^a   Yehia, Soad Aly ^b   Kassem, Mahfouz Abd El Megeid ^a   Mostafa, Dina Mahmoud ^a   Nasr, Essam Amin ^c   Asfour, Marwa Hasanin ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Agricultural Research Center   (Egypt)

Author keywords

Biological evaluation; Characterization; Intracellular targeting; Nano drug delivery; Tuberculosis

Indexed keywords

ETHAMBUTOL; NIOSOME; DELAYED RELEASE FORMULATION; LIPOSOME; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; GUINEA PIG; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG HOMOGENATE; LUNG WEIGHT; MOUSE; NANOENCAPSULATION; NONHUMAN; PARAMETERS; TUBERCULOSIS; ZETA POTENTIAL; ANIMAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; LUNG; MEDICINAL CHEMISTRY; METABOLISM; TIME; TISSUE DISTRIBUTION;

ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ETHAMBUTOL; GUINEA PIGS; LIPOSOMES; LUNG; MICE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84920285657     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.868556     Document Type: Article

References (67)

1. Abd-Elbary A, El-Laithy HM, Tadros MI. (2008). Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 357:189-98.
2. Abdelkader H, Wu Z, Al-Kassas R, Alany RG. (2012). Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects. Int J Pharm 433:142-8.
3. Aboelwafa AA, El-Setouhy DA, Elmeshad AN. (2010). Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design. AAPS Pharm Sci Tech 11:1591-602.
4. Aggarwal D, Kaur IP. (2005). Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 290:155-9.
5. Baillie AJ, Coombs GH, Dolan TF, Laurie J. (1986). Non-ionic surfactant vesicles, niosomes, as a delivery system for the antileishmanial drug, sodium stibogluconate. J Pharm Pharmacol 38:502-5.
6. Baillie AJ, Florence AT, Hume LR, et al. (1985). The preparation and properties of niosomes non-ionic surfactant vesicles. J Pharm Pharmacol 37:863-8.
7. Balakrishnan P, Shanmugam S, Lee WS, et al. (2009). Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 377:1-8.
8. Banchroft JD, Stevens A, Turner DR. (1996). Theory and practice of histological techniques. New York, London, San Francisco, Tokyo: Churchil Livingstone.
9. Bhaskaran S, Harish CG, Lakshmi PK. (2011). Methotrexate liposome as oral drug delivery carriers. J Pharm Res 4:3237-40.
10. Biju SS, Talegaonkar S, Mishra PR, Khar RK. (2006). Vesicular systems: an overview. Indian J Pharm Sci 68:141-53.
11. Briones E, Colino CI, Lanao JM. (2008). Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Rel 125:210-27.
12. Cable C. (1989). An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. Ph. D. Thesis, Strathclyde, Glasgow, UK.
13. Carafa M, Santucci E, Alhaique F, et al. (1998). preparation and properties of new unilamellar non-ionic surfactant vesicles. Int J Pharm 160:51-9.
14. Cortesi R, Esposito E, Corradini F, et al. (2007). Non-phospholipid vesicles as carriers for peptides and proteins: production, characterization and stability studies. Int J Pharm 339:52-60.
15. Deol P, Khuller GK, Joshi K. (1997). Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 41:1211-4.
16. El-Laithy HM, Shoukry O, Mahran LG. (2011). Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm 77:43-55.
17. El-Ridy MS, Abd El-Bary AA, El-Gazayrly O, et al. Study of niosomal encapsulation for the antitubercular drug, isoniazid. The Fourth International Conference of Pharmaceutical and Drug Industries Division; 2009 NRC, Cairo, Egypt.
18. El-Ridy MS, Abdelbary A, Essam T, et al. (2011a). Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm 37:1491-508.
19. El-Ridy MS, Abdelbary A, Nasr EA, et al. (2011b). Niosomal encapsulation of the antitubercular drug, pyrazinamide. Drug Dev Ind Pharm 37:1110-8.
20. El-Ridy MS, Abdelbary A, Khalil RM, et al. (2008). Niosomal encapsulation of the tuberculocidal drug rifampicin. Egypt Pharm J (NRC) 7:69-83.
21. El-Ridy MS, Badawi AA, Safar MM, Mohsen AM. (2012). Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin. Int J Pharm Pharmaceut Sci 4:549-59.
22. El-Ridy MS, Kassem M, Akbarieh M, Tawashi R. (1988). The effect of surface charge of liposomes on aggregation in the buccal cavity. Proceeding of the 15th International Symposium on Controlled Release of Bioactive Materials, Basel, Switzerland, 344, No. 200.
23. El-Ridy MS, Mostafa DM, Shehab A, et al. (2007). Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm 330:82-8.
24. El-Ridy MS, Shehab A, Emmara LM, Moustafa DM. (2005). A three month chemoprophylaxis of Schistosomiasis using liposomeencapsulated oxamniquine. Bull NRC Egypt 30:57-72.
25. Farrar K. (1988). Tuberculosis and its treatment. Pharm J 240:149-51.
26. Global Tuberculosis Report (2012). Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf [Online].
27. Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71-82.
28. Hao Y, Zhao F, Li N, et al. (2002). Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm 244:73-80.
29. Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharm Sci Tech 8:E1-2.
30. Jiang Z, Wang H, Locke DC. (2002). Determination of ethambutol by ion-pair reversed phase liquid chromatography with UV detection. Anal Chim Acta 456:189-92.
31. Kakkar R, Rekha R, Kumar DN, Sanju N. (2011). Formulation and characterisation of valsartan proniosomes. Maejo Int J Sci Technol 5:146-58.
32. Karlson AG. (1961). Therapeutic effect of ethambutol (dextro-2, 2'-[ethylene-diimino]-di-1-butanol) on experimental tuberculosis in guinea pigs. Amer Rev Resp Dis 84:902-4.
33. Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol 27:48-9.
34. Kumar GP, Rajeshwarrao P. (2011). Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharm Sinica B 1:208-19.
35. Kumar MR, Aithal BK, Udupa N, et al. (2011). Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma. Drug Deliv 18:511-22.
36. Lee CS, Brater DC, Gambertoglio JG, Benet LZ. (1980). Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm 8:335-46.
37. Lee CS, Gambertoglio JG, Brater DC, Benet LZ. (1977). Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther 22:615-21.
38. Liu Y, Miyoshi H, Nakamura M. (2007). Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120:2527-37.
39. Manconi M, Sinico C, Valenti D, et al. (2006). Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicleincorporated tretinoin. Int J Pharm 311:11-9.
40. Manosroi A, Wongtrakul P, Manosroi J, et al. (2003). Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloid Surf B: Biointerfaces 30:129-38.
41. Marks J. (1972). Ending the routine guinea-pig test. Tubercle 53:31-4.
42. Martindale. (2011). The complete drug reference. In: Sweetman SC, ed. The extra pharmacopoeia. 37 edn. London: Pharmaceutical Press.
43. Material Safety Data Sheets (2003). Sorbitan trioleate, SPAN® 85, Uniqema, International business of Imperical Chemical Industries PLC. [Online].
44. Material Safety Data Sheets (2012). Sorbitan monostearate (Span 60) MSDS, science lab.com [Online]. science lab.com. (Last ubdated 6/9/2012)].
45. Meers P, Neville M, Malinin V, et al. (2008). Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 61:859-68.
46. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. (2008). Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 361:104-11.
47. Muzzalupo R, Nicoletta FP, Trombino S, et al. (2007). A new crown ether as vesicular carrier for 5-fluoruracil: synthesis, characterization and drug delivery evaluation. Colloids Surf B: Biointerfaces 58:197-202.
48. Muzzalupo R, Trombino S, Iemma F, et al. (2005). Preparation and characterization of bolaform surfactant vesicles. Colloids Surf B: Biointerfaces 46:78-83.
49. Nagarsenker MS, Joshi AA. (1997). Preparation, characterization and evaluation of liposomal dispersions of lidocaine. Drug Dev Ind Pharm 23:1159-65.
50. Nasr M, Mansour S, Mortada ND, Elshamy AA. (2008). Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J Microencap 25:499-512.
51. Orozco LC, Quintana FO, Beltran RM, et al. (1986). The use of rifampicin and isoniazid entrapped in liposomes for the treatment of Murine tuberculosis. Tubercle 67:91-7.
52. Palozza P, Muzzalupo R, Trombino S, et al. (2006). Solubilization and stabilization of β-carotene in niosomes: delivery to cultured cells. Chem Phys Lip 139:32-42.
53. Pandey R, Khuller GK. (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85:227-34.
54. Pardakhty A, Varshosaz J, Rouholamini A. (2007). In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 328:130-41.
55. Peloquin CA, Bulpitt AE, Jaresko GS, et al. (1999). Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 43:568-72.
56. Pereira-Lachataignerais J, Pons R, Panizza P, et al. (2006). Study and formation of vesicle systems with low polydispersity index by ultrasound method. Chem Phys Lip 140:88-97.
57. Qurrat-ul A, Sharma S, Khuller GK, Garg SK (2003). Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother 51:931-8.
58. Rogerson A, Cummings J, Florence AT. (1987). Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencap 4:321-8.
59. Ruckmani K, Jayakar B, Ghosal SK. (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Dev Ind Pharm 26:217-22.
60. Sathyavathi V, Abdul Hasansathali A, Ilavarasan R, Sangeetha T. (2012). Formulation and evaluation of niosomal in situ gel ocular delivery system of brimonidine tartrate. Pharm Sci 2: L-82-95.
61. Shi B, Fang C, Pei Y. (2006). Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci 95:1873-87.
62. Singh CH, Jain CP, Kumar BN. (2011a). Formulation, characterization, stability and in vitro evaluation of nimesulide niosomes. Pharmacophore 2:168-85.
63. Singh G, Dwivedi H, Saraf SK, Saraf SA. (2011b). Niosomal delivery of isoniazid-development and characterization. Trop J Pharm Res 10:203-10.
64. Thomas JP, Durr FE. (1983). Ethambutol dose-plasma level correlation studies in guinea pigs. Am Rev Respir Dis 6127:352-3.
65. Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci 58:1-55.
66. Xu ZP, Zeng QH, Lu GQ, Yu AB. (2006). Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 61:1027-40.
67. Yoshioka T, Sternberg B, Florence AT. (1994). Preparation and properties of vesicles (niosomes) of sorbitan monoesters (span-20, span-40, span-60 and span-80) and a sorbitan triester (span-85). Int J Pharm 105:1-6.